{"nctId":"NCT03529942","briefTitle":"Study to Evaluate the Effect of FX006 on Synovial Inflammation in Patients With OA of the Knee","startDateStruct":{"date":"2018-04-24","type":"ACTUAL"},"conditions":["Osteoarthritis, Knee"],"count":129,"armGroups":[{"label":"FX006 32 mg","type":"EXPERIMENTAL","interventionNames":["Drug: FX006 32 mg"]}],"interventions":[{"name":"FX006 32 mg","otherNames":["Zilretta"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Written consent to participate in the study\n* Male or female ≥ 40 years of age\n* Body mass index (BMI) ≤ 40 kg/m\\^2\n* Ambulatory and in good general health\n* Willing and able to comply with the study procedures and visit schedules and able to follow verbal and written instructions\n* Willing to abstain from use of protocol-restricted medications during the study\n* Symptoms associated with OA of the index knee for ≥ 6 months prior to Screening (patient self-report is acceptable)\n* Currently meets American College of Rheumatology (ACR) Criteria (clinical and radiological) for OA\n* Kellgren-Lawrence (K-L) Grade 2 or 3 in the index knee based on X-ray performed during Screening (centrally read)\n\nExclusion Criteria:\n\n* Any inflammatory arthritis including reactive arthritis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, arthritis associated with inflammatory bowel disease, gout or secondary OA from gout\n* History of infection or crystal disease in the index knee joint\n* Unstable index knee joint (such as a torn anterior cruciate ligament) within 12 months of Screening\n* Surgery or arthroscopy of the index knee within 12 months of Screening\n* IA corticosteroid (investigational or marketed) in any joint within 3 months of Screening\n* IA treatment of the index knee with hyaluronic acid (investigational or marketed) within 6 months of Screening\n* IV or IM corticosteroids (investigational or marketed) within 3 months of Screening\n* Oral corticosteroids (investigational or marketed) within 1 month of Screening\n* Any other IA drug/biologic in the index knee within 6 months of Screening or 5 half-lives (whichever is longer) (e.g., platelet rich plasma (PRP) injection, stem cells, prolotherapy and amniotic fluid injection)\n* Prior administration of FX006\n* eGFR results \\<40 mL/minute\n* Any contraindication to MRI Scanning (e.g., presence of certain ferromagnetic foreign bodies or electronic devices including most cardiac pacemakers, claustrophobia)\n* Known hypersensitivity to any form of radiographic contrast\n* Females who are pregnant or nursing or plan to become pregnant during the study; men who plan to conceive during the study","healthyVolunteers":false,"sex":"ALL","minimumAge":"40 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Mean Standardized Change in Synovial Volume (SV) at 6 Weeks","description":"Synovial volume (mm\\^3) as measured by MRI and read by a central imaging vendor. Standardization was performed by dividing the model-derived least squares means and corresponding confidence intervals by the adjusted standard deviation (SD). Therefore, the mean standardized change represents the change in synovial volume expressed in standard deviation units.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.67","spread":null},{"groupId":"OG001","value":"-0.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Absolute Change in Synovial Volume at 6 Weeks","description":"Mean absolute change from baseline at 6 weeks in synovial volume (mm\\^3) as measured by MRI and read by a central imaging vendor. The least squares mean changes are estimated using a mixed effects model for repeated measures with fixed effects for study time point, study site, baseline score and baseline femur bone volume (mm\\^3) and a random effect for patient.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5469.68","spread":"581.9123"},{"groupId":"OG001","value":"-7549.55","spread":"683.6488"}]}]}]},{"type":"SECONDARY","title":"Mean Standardized Change in Synovial Volume (SV) at 24 Weeks","description":"Synovial volume (mm\\^3) as measured by MRI and read by a central imaging vendor. Standardization was performed by dividing the model-derived least squares means and corresponding confidence intervals by the adjusted standard deviation (SD). Therefore, the mean standardized change represents the change in synovial volume expressed in standard deviation units.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.20","spread":null},{"groupId":"OG001","value":"0.20","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Absolute Change in Synovial Volume at 24 Weeks","description":"Mean absolute change (mm\\^3) from baseline at 24 weeks in synovial volume (mm\\^3) as measured by MRI and read by a central imaging vendor. The least squares mean changes are estimated using a mixed effects model for repeated measures with fixed effects for study time point, study site, baseline score and baseline femur bone volume (mm\\^3) and a random effect for patient.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3239.94","spread":"1184.5800"},{"groupId":"OG001","value":"3476.52","spread":"1408.7997"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":129},"commonTop":["Arthralgia","Oedema Peripheral","Upper Respiratory Tract Infection","Back Pain","Dizziness"]}}}